BridgeMD
MEPI-AVC - Evaluation of the efficacy and safety of mepivacaine on the neurological sequelae of cerabral infarction
EU CTIS ID: 2024-514481-39-00
What this study is testing
To assess, in patients with neurological symptoms following ischemic stroke, the rate of responders to an injection of mepivatin subcutaneously
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Ischemic stroke more than 30 days old Age between 18 and 85 years old At least one deficit among: motor deficit: score < 56 on the Fugl-Meyer scale aphasia: score ≥4 on the Aphasia Rapid Test, presence of a clinically observable visual scotoma Having given their written consent Be affiliated with a social security scheme, Universal Medical Coverage (CMU) or any equivalent scheme
You likely can't join if
- Hypersensitivity to amide-bonded local anesthetics. Atrioventricular conduction disorders requiring permanent electro-systolic training not yet performed. Epilepsy not controlled by treatment. Porphyritic subjects. Patients with a motor deficit (but no aphasia or scotomas) in whom there is spasticity leading to a major reduction in joint amplitude in passive motion Minor patients, under curatorship or guardianship, under legal protection, deprived of liberty, pregnant or breastfeeding women Pathologies involving the vital prognosis or compromising follow-up during the study period Patient undergoing local amine anesthesia in the 7 days preceding V1. Patients currently treated with no anti-arrhythmics such as tocainide, aprindine and mexiletine Patients with a contraindication to MRI (ferro-magnetic surgical clips, eye implants, metallic foreign body intraocular or in the nervous system, implants or metallic objects likely to contain the radiofrequency field, cochlear implants, cerebral or cardiac pacemaker , implantable cardiac defibrillators) Patients participating in research involving the therapeutic human person who may modify functional recovery (whether by medication or by medical device) or subject to an exclusion period for another research
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.